Shares of biotechnology company Curis Inc (NASDAQ: CRIS) are surging premarket after the company reported positive preliminary data from its ongoing open-label, single-arm Phase 1 dose-escalation study of CA-4948.
The drug is used to treat patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndromes (MDS).
The primary objective of the study is to determine the maximum tolerated dose and a recommended Phase 2 dose for CA-4948.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
The study found that marrow blast reductions were observed in all six evaluable patients, with six of seven patients enrolled still on the study, two patients experienced a marrow complete response, and no dose-limiting toxicities were observed.
“We are highly encouraged by the breadth of clinical activity with CA-4948 seen with this early data, especially as this study is both monotherapy and in a late line, relapsed/refractory population,” commented James Dentzer, President and CEO of Curis.
The company’s stock price has skyrocketed premarket, currently trading 201% higher at $4.34 per share, its highest level since 2018, after closing Monday’s session at $1.44.
PEOPLE WHO READ THIS ALSO VIEWED:
- Sareum shares surged today, here’s why
- Trade stocks with eToro
- Key stock market statistics for 2020